HIMS vs. TDOC: Which Telehealth Stock Looks More Compelling?

Zacks compares Hims & Hers (HIMS) and Teladoc (TDOC), noting HIMS has underperformed TDOC over the past three months (HIMS -37.4% vs TDOC -9.7%) but outperformed over the past year (+22.1% vs TDOC -22.5%). HIMS trades at a forward 12‑month P/S of 2.9x (above its 3‑year median) while TDOC sits at 0.5x (below its median); Zacks expects HIMS 2025 EPS to improve ~77.8% year-over-year and TDOC’s 2025 loss to narrow ~79.7%. Analyst averages imply ~31.9% upside for HIMS ($45.92) and ~27.3% for TDOC ($9.18); Zacks favors HIMS for its diagnostics expansion, new specialty offerings (oral testosterone KYZATREX planned for 2026) and international M&A, while noting Teladoc’s enterprise Integrated Care and BetterHelp execution supports stability but carries exposure to enterprise demand cycles.

Analysis

Market structure: Digital-first consumer platforms (HIMS) and enterprise virtual care (TDOC) are bifurcating demand — consumers favor subscription, convenience and integrated pharmacy while employers/health systems prioritize breadth and clinical depth. HIMS’s higher forward P/S (2.9x) vs TDOC (0.5x) signals market pricing of execution risk vs enterprise cyclicality; recurring-revenue models give HIMS stronger gross-margin scalability but greater sensitivity to consumer CAC. Cross-asset: further multiple expansion in growth names would tighten high-yield spreads and lift long-duration assets; a disorderly macro shock (rates up) would compress both equities and telehealth private financings quickly.

Risk assessment: Tail risks include regulatory limits on remote prescribing or cross-border pharmacy fulfillment, a material data breach, or an employer-driven pullback in virtual care budgets — each could cut revenue 15–40% for affected segments. Time horizons: immediate (days) — earnings/analyst revisions; short-term (3–6 months) — BetterHelp insurance deals, UK/Canada rollouts; long-term (12–24 months) — product launches (KYZATREX 2026) and hospital Clarity deployments. Hidden dependencies: reliance on lab/pharmacy partners, payer reimbursement decisions, and international regulatory approvals.

Trade implications: Tactical: establish a 2–3% long position in HIMS over next 10 trading days targeting ~+30% to $45.9 in 6–12 months with a 18–20% stop; fund via trimming 3–5% exposure in legacy hospital/med-tech incumbents. Hedge/option: buy 12–24 month TDOC LEAP call spread (buy lower strike, sell higher) sized 0.8–1% to capture asymmetric recovery while limiting premium; alternatively run a pair trade long HIMS / short TDOC equal-dollar 1.5% to express subscription vs enterprise secular divergence. Entry/exit: sell HIMS into strength above analyst PT or if forward P/S >3.5x; recycle if TDOC BetterHelp insurance acceptance materially accelerates within 90 days.

Contrarian angles: Consensus underestimates TDOC’s valuation optionality — at 0.5x P/S a favorable insurer or Medicare policy shift could produce >50% upside; conversely HIMS pricing appears to bake near-perfect international and product execution. Reaction may be underdone on TDOC downside if enterprise budgets cut (earnings gap risk 20–30%) and overdone on HIMS if CAC inflates or KYZATREX delays beyond 2026. Historical parallel: telemedicine cycles (2019–21) show fast adoption can reverse quickly with policy shifts; prioritize catalyst-based sizing and explicit stop/risk limits.

Key Decisions for Investors

• Establish a 2–3% long position in HIMS within the next 10 trading days, targeting ~+30% (to $45.9) over 6–12 months; set a hard stop-loss at 18–20% below entry and reduce position if forward P/S >3.5x or international launches materially underperform in 2 consecutive quarters.
• Deploy a smaller asymmetric position in TDOC using a 12–24 month call spread (buy LEAP calls, sell higher strike to finance) sized 0.8–1% of portfolio to capture upside from insurer/Medicare adoption while capping premium — reassess after next 2 quarterly reports or if analyst consensus EPS loss improves >50% year-over-year.
• Implement a pair trade: long HIMS (1.5%) / short TDOC (1.5%) to express conviction in consumer subscription strength versus enterprise cyclicality; unwind or rebalance if TDOC wins >1 major payer/health-system contract or HIMS misses retention targets for two consecutive quarters.
• Shift 3–5% of healthcare allocation from legacy hospital/medical-equipment names into digital health exposure (HIMS/TDOC mix per above) over 30 days to reflect secular digital substitution; monitor high-yield spread moves — if BAA spreads widen >75bp quickly, reduce growth exposure by 50%.
• Monitor regulatory catalysts over next 30–60 days: CMS telehealth guidance, DEA remote-prescribing rules, and UK/EU digital health approvals; if any policy narrows remote-prescribing or raises compliance costs, trim HIMS by 50% and close TDOC optional longs.